On May 22, the 6th I-RNA Nucleic Acid Therapeutics Industry Summit 2026 convened in Suzhou, marking a pivotal moment as nucleic acid drugs transition from laboratory research into broad clinical application. Bringing together top industry leaders and key decision-makers, the summit provided a panoramic discussion on innovation and clinical translation pathways—spanning cutting-edge R&D, strategic planning, technical hurdles, and emerging opportunities. Sirnaomics CEO Dr. H Fai Poon was invited to the flagship roundtable, where he engaged in an in-depth discussion under the theme “Delivery Duel: Who Will Define the Future of Nucleic Acid Drugs?” His incisive analysis of the industry’s core barriers and competitive landscape drew widespread attention.

During the roundtable, Dr. Poon revisited his pioneering 2004 nucleic acid study, which first explored repairing brain neuronal cells using nucleic acid technology. His early work clearly identified poor delivery efficiency and imprecise targeting as the critical barriers to clinical translation, leading him to foresee that delivery would become the ultimate bottleneck constraining the entire nucleic acid industry. This early insight, which continues to profoundly shape the industry’s direction, laid the strategic foundation for Sirnaomics’ long-term commitment to delivery technology.

（Pictured above, second from left: Dr. H Fai Poon, CEO of Sirnaomics）

Facing the escalating challenges of delivery, Dr. Poon shared his enduring scientific philosophy: “Bold exploration, rigorous validation.” He pointed out that the most transformative biomedical breakthroughs often arise from unexpected experimental discoveries. Only by daring to innovate through trial and error, while upholding the strictest scientific verification, can the long-standing bottlenecks that constrain the industry be truly overcome. This mindset—merging courage with precision—has become the intrinsic driving force behind the continuous evolution of Sirnaomics’ delivery platforms.

Dr. Poon emphasized that RNA drug competition has now centered entirely on delivery platforms, predicting that systemic improvements in delivery will be achieved within the next three years. Against this backdrop, Sirnaomics’ proprietary PNP delivery platform has demonstrated standout performance. Phase II clinical results for the core product STP705 have validated its stable, safe, and efficient extrahepatic delivery capability, positioning the PNP platform as one of the very few delivery systems globally with Phase II clinical evidence for extrahepatic indications. Leveraging its high plasticity and broad scientific potential, the PNP platform is steadily expanding into multi-tissue, multi-indication, and multi-scenario RNA drug development, demonstrating immense promise.

Today, Sirnaomics remains dedicated to developing RNAi therapeutics in areas including oncology, medical aesthetics and localized fat reduction, and cardiovascular diseases. The company has established a diversified technology portfolio encompassing the Polypeptide Nanoparticle (PNP) delivery platform and the GalAhead™ delivery platform. Looking ahead, Sirnaomics will continue to make delivery technology its core strategic pillar, joining hands with industry partners to move nucleic acid medicines decisively from concept to clinic and deliver more groundbreaking treatment options to patients worldwide.